PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 8440 (117th)

Right to Try Clarification Act

referredUnited States· United States Congress· EN

Introduced

20 July 2022

Last action

1 November 2022 · Referred

Status

Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.

Sponsors

Earl Blumenauer, Nancy Mace, Rep. Dean, Madeleine [D-PA-4], Andy Biggs, Rep. Correa, J. Luis [D-CA-46], Del. Norton, Eleanor Holmes [D-DC-At Large]

Subjects

Healthcare

Source updated

5 December 2025

Healthcare

Summary

Right to Try Clarification Act This bill specifies that investigational drugs that are provided directly to individuals from manufacturers without the need for federal regulatory approval (i.e., via the Right to Try pathway) are exempt from restrictions that would otherwise apply under the Controlled Substances Act (e.g., restrictions on the use or possession of schedule I controlled substances).

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 20 July 2022

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  2. 20 July 2022

    Introduced

    Sponsor introductory remarks on measure. (CR E757)

    Source: IntroReferral

  3. 20 July 2022

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 20 July 2022

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 1 November 2022

    Referred

    Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.